CN Patent

CN117143077A — 来那替尼马来酸盐及晶形

Assigned to Wyeth LLC · Expires 2023-12-01 · 2y expired

What this patent protects

本发明涉及(E)‑N‑{4‑[3‑氯‑4‑(2‑吡啶基甲氧基)苯胺基]‑3‑氰基‑7‑乙氧基‑6‑喹啉基}‑4‑(二甲基氨基)‑2‑丁烯酰胺的马来酸盐形式，制备结晶马来酸盐形式的方法，和有关的化合物，以及包含它们的药物组合物。所述马来酸盐可用于治疗癌、特别是受表皮生长因子受体家族激酶影响的那些癌。

USPTO Abstract

本发明涉及(E)‑N‑{4‑[3‑氯‑4‑(2‑吡啶基甲氧基)苯胺基]‑3‑氰基‑7‑乙氧基‑6‑喹啉基}‑4‑(二甲基氨基)‑2‑丁烯酰胺的马来酸盐形式，制备结晶马来酸盐形式的方法，和有关的化合物，以及包含它们的药物组合物。所述马来酸盐可用于治疗癌、特别是受表皮生长因子受体家族激酶影响的那些癌。

Drugs covered by this patent

Patent Metadata

Patent number
CN117143077A
Jurisdiction
CN
Classification
—
Expires
2023-12-01
Drug substance claim
No
Drug product claim
No
Assignee
Wyeth LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.